14 unknown, 2 completed, 2 recruiting, 1 not yet recruiting. 13 Phase 4, 5 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 13 | Unknown 12, Completed 1 |
| Phase 2 | 5 | Recruiting 2, Unknown 2, Completed 1 |
| Phase 1 | 4 | Recruiting 2, Not yet recruiting 1, Unknown 1 |
Follow Mingzhi Zhang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors CAR-T Therapy - CAR-T Cell Therapy, Lymphomas | Phase 1 | Not yet recruiting | Mingzhi Zhang | 30 | 2024-12-01 | 2024-10-17 |
| A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone - Newly Diagnosed Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Mingzhi Zhang | 80 | 2024-11-20 | 2024-11-12 |
| "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL Selinexor+pegaspargase+dexamethasone - NKTCL, Selinexor | Phase 1 / Phase 2 | Recruiting | Mingzhi Zhang | 50 | 2024-09-01 | 2025-07-14 |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma the dose-escalation phase - Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Unknown | Mingzhi Zhang | 40 | 2021-03-29 | 2022-06-02 |
| Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma rituximab in combination with methotrexate, cytarabine and dexamethasone - Primary Central Nervous System Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 20 | 2019-09-05 | 2019-09-10 |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma PD-1 blocking antibody, chidamide, lenalidomide and gemcitabine - Peripheral T-cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 100 | 2019-09-01 | 2020-05-12 |
| PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma PD-1 Antibody, chidamide, lenalidomide and etoposide - NK/T Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 50 | 2019-04-01 | 2019-07-30 |
| Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Crizotinib, Etoposide Capsule, Auto-HSCT - ALK-Positive Anaplastic Large Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 20 | 2018-10-01 | 2018-10-16 |
| A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma CODOX-M/IVAC, Decitabine - T-lymphoblastic Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 40 | 2018-06-01 | 2018-09-14 |
| A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Decitabine - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 60 | 2018-06-01 | 2018-09-14 |
| Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma (R)-CHOP regimen, (R)-CVP regimen - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 20 | 2017-07-01 | 2018-05-01 |
| Treatment of Primary CNS Lymphoma ( FTD ) HD-MTX-Ara-C regimen, FTD regimen - Primary CNS Lymphoma (PCNSL) | Phase 2 | Completed | Mingzhi Zhang | 20 | 2017-03-02 | 2022-03-10 |
| Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma Pembrolizumab (PD-1 Blocking Antibody) - Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | Unknown | Mingzhi Zhang | 20 | 2017-02-19 | 2017-04-11 |
| A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Chidamide+ Etoposide - NK/T-Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 30 | 2016-10-01 | 2020-07-29 |
| Treatment of Diffuse Large B Cell Lymphoma Yangzhengxiaoji capsule combined with CHOP regimen, CHOP regimen - Diffuse Large B Cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 120 | 2012-09-01 | 2015-12-30 |
| Treatment of Primary CNS Lymphoma HD-MTX-Ara-C regimen, FVD regimen - Primary CNS Lymphoma (PCNSL) | Phase 4 | Unknown | Mingzhi Zhang | 50 | 2012-06-01 | 2015-07-21 |
| Treatment of Peripheral T-cell Lymphoma GDPT regimen, CHOP regimen - Peripheral T-cell Lymphoma | Phase 4 | Completed | Mingzhi Zhang | 100 | 2011-08-01 | 2016-10-05 |
| Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna） - Nasal and Nasal-type NK/T-cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 80 | 2011-01-01 | 2015-07-17 |
| Treatment of Natural Killer/T Cell Lymphoma-I/II DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase), VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）, gemcitabine,pegaspargase,cisplatin,dexamethasone - Nasal and Nasal-type NK/T-cell Lymphoma | Phase 4 | Unknown | Mingzhi Zhang | 200 | 2011-01-01 | 2015-07-17 |
Lymphoma, Extranodal NK-T-Cell (5) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, T-Cell, Peripheral (2) · Lymphoma (1) · Myeloproliferative Syndrome, Transient (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Decitabine (3) · Cytarabine (2) · Dexamethasone (2) · Etoposide (2) · Gemcitabine (2) · Lenalidomide (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · Rituximab (2) · VAP-cyclo protocol (2) · Cisplatin (1) · Crizotinib (1) · Drug Therapy (1) · Immunotherapy, Adoptive (1) · Methotrexate (1) · Prednisone (1)
China (19)
PMID 27060152, PMID 27384676, PMID 28597542, PMID 31118779, PMID 32550864, PMID 33034052, PMID 34222013, PMID 35708709, PMID 41485126